Find our press release as a PDF here in addition to being found below. First investigational drug selected for testing in innovative CATALYST clinical trial programme in 12 UK centres led by University Hospitals Birmingham, Europe’s largest integrated critical care centre Investigational therapy developed to treat rheumatoid arthritis could be potential therapy for hospitalised COVID-19 patients…Read More
Find our press release as a PDF here in addition to being found below. Emergency access granted to investigational therapy Objective to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation Discussions with international regulators, KOLs and clinical centres of excellence are ongoing to progress namilumab OXFORD, England, April 06, 2020 – Izana…Read More
Oxford, UK – 13 August 2018: Izana Bioscience, a biopharmaceutical company focused on translational medicine, today announced the initiation of a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis, a debilitating arthritic disease of the spine that affects millions of people worldwide. The randomized, double-blind, placebo-controlled NAMASTE study (Namilumab in Ankylosing Spondylitis Therapy) will enrol over 40…Read More
Find our press release as a PDF here in addition to being found below. Namilumab exclusive worldwide licence granted by Takeda Awarded £1.35 million grant by Innovate UK to support phase II proof-of-concept study Highly experienced management team; co-founded by serial entrepreneur Bryan Morton Oxford, UK – 14 December 2017: Izana Bioscience (“Izana” or “the Company”) launches…Read More
Send us an email using the form and one of the team will be in touch with you soon.